A Multicenter, Open-Label, Randomized Study Comparing Efficacy and Safety of S-1 as Single Agent Versus 5-FU Bolus for the Treatment of Patients With Metastatic Pancreatic Cancer Previously Treated With a Gemcitabine-Based Regimen
Latest Information Update: 20 Jan 2022
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Fluorouracil
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- 19 Jan 2022 This trial has been completed in Greece (End Date: 22 Mar 2010), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 05 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.